Search

everythinglearnresearchcommunity

for

Search:↓

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.

Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.

Mogamulizumab can cause hair loss and skin rashes.

Early use of infliximab in severe pediatric Crohn's disease can lead to significant improvement and remission.

Secukinumab reduces immune activity in hidradenitis suppurativa skin.

Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.

Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.

Higher levels of IL-1R1 and hsa-miR-19b-3p may help diagnose and predict alopecia areata severity.

Dupilumab helped an 11-year-old boy regrow hair and reduce skin rashes.

Anti-TNF therapy can cause hair loss and skin issues.

Hyaluronate fragments can help reverse skin thinning by working with the CD44 receptor.

A woman developed lupus after taking hydroxyurea for two years.

Stopping infliximab and using strong topical steroids can regrow hair lost due to psoriasiform alopecia.

HLA can be linked to autoimmune hepatitis.

The new delivery system improves Alzheimer's symptoms by releasing Huperzine A slowly and effectively.

Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.

Human TMEM2 does not break down hyaluronan but helps control its metabolism.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

Efalizumab can cause unexpected excessive hair growth.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

The new microneedle patch effectively treats alopecia areata with fewer side effects than oral medication.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

Dupilumab may help regrow hair in people with atopic dermatitis.

Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

The non-cross-linked hyaluronic acid compound effectively and safely improves keratosis pilaris.